Sealand Securities: The concerted actors of the actual controller have completed the internal equity structure adjustment and share transferZhitong·Nov 3, 2025 at 05:52 AM0007500.00%600252+3.48%
Zhongheng Group: Net profit loss of 2.4372 million yuan in the third quarterZhitong·Oct 30, 2025 at 05:57 AM600252+3.48%
Zhongheng Group: Net profit of 27.0776 million yuan in the first half of 2025, a year-on-year increase of 23.59%Zhitong·Aug 29, 2025 at 09:12 AM600252+3.48%
Zhongheng Group: Wholly-owned subsidiary Zhongheng Innovation acquires a drug technology for treating chronic heart failure for 55 million yuanZhitong·Aug 4, 2025 at 05:35 AM600252+3.48%
Zhongheng Group: Has repurchased 99.5909 million shares, with a total amount of funds used of 249 million yuanZhitong·Jul 18, 2025 at 08:39 PM600252+3.48%
LaiMei Pharmaceutical: Guangtou Group plans to increase capital and expand shares in Guangtou JinKong with 25.94% of Zhongheng Group sharesZhitong·May 30, 2025 at 04:59 AM600252+3.48%
Zhongheng Group has repurchased a total of 42.147 million shares, costing 101 million yuanZhitong·May 6, 2025 at 06:10 AM600252+3.48%
Zhongheng Group's wholly-owned subsidiary has received the approval notice for drug clinical trialsZhitong·Apr 15, 2025 at 05:17 AM600252+3.48%
Zhongheng Group: Plans to repurchase shares for 300 million to 500 million yuanZhitong·Apr 1, 2025 at 05:37 AM600252+3.48%
Zhongheng Group's subsidiary Wuzhou Pharmaceutical plans to be selected for the centralized bulk purchasing of traditional Chinese medicine by the National Traditional Chinese Medicine Procurement AllianceZhitong·Feb 24, 2025 at 03:46 AM600252+3.48%
Overview of the lifting of restrictions on the circulation of A-shares | February 11Zhitong·Feb 10, 2025 at 07:01 PM600252+3.48%000002-3.30%
Zhongheng Group: Application for clinical trial of Sanqi granules acceptedZhitong·Jan 26, 2025 at 02:50 AM600252+3.48%
